Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.

Cancer chemotherapy and pharmacology - 1 Mar 2015

Chang T C, Shiah H S, Yang C H, Yeh K H, Cheng A L, Shen B N, Wang Y W, Yeh C G, Chiang N J, Chang J Y, Chen L T

Abstract excerpt

PURPOSE: To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. METHODS: Patients were enrolled in cohorts of one to three to receive escalating dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin
Share to Half-Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infusions, Intravenous

Share to Irinotecan

Share to Liposomes

Share to Maximum Tolerated Dose

Share to Nanoparticles

Source

Open in PubMed Open full text

Identifiers

PMID: 25577133
DOI: 10.1007/s00280-014-2671-x
PMCID: PMC4341010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25577133-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.PMID 25577133Read ↗

Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.Semantic proximity Read ↗

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.Semantic proximity Read ↗

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.Semantic proximity Read ↗

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.Semantic proximity Read ↗

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.Semantic proximity Read ↗

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid TumorsSemantic proximity Read ↗

Safety and Tolerability of OncoRob © in Patients with Advanced Malignant Solid Tumors under Compassionate Use.Semantic proximity Read ↗

Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.Semantic proximity Read ↗

Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects.Semantic proximity Read ↗

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.Semantic proximity Read ↗

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.Semantic proximity Read ↗

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.